Immunotherapy with engineered bacteria by targeting the STING pathway for anti-tumor immunity
Synthetic biology can be used to create rationally designed living therapeutics. Here the authors engineer E. coli Nissle to target STING activation in antigen presenting cells for the treatment of solid tumors and demonstrate preclinical activity in murine models.
Guardado en:
Autores principales: | Daniel S. Leventhal, Anna Sokolovska, Ning Li, Christopher Plescia, Starsha A. Kolodziej, Carey W. Gallant, Rudy Christmas, Jian-Rong Gao, Michael J. James, Andres Abin-Fuentes, Munira Momin, Christopher Bergeron, Adam Fisher, Paul F. Miller, Kip A. West, Jose M. Lora |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2020
|
Materias: | |
Acceso en línea: | https://doaj.org/article/c274837c940442a5b5b9051d086275aa |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
ExoSTING, an extracellular vesicle loaded with STING agonists, promotes tumor immune surveillance
por: Su Chul Jang, et al.
Publicado: (2021) -
STING Signaling and Skin Cancers
por: Sayaka Sato, et al.
Publicado: (2021) -
Management of corneal bee sting
por: Razmjoo H, et al.
Publicado: (2011) -
Stinging Trichomes in Apocynaceae and Their Evolution in Angiosperms
por: Maria Camila Medina, et al.
Publicado: (2021) -
Activation of STING requires palmitoylation at the Golgi
por: Kojiro Mukai, et al.
Publicado: (2016)